ReviewParkinson's disease2017
Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease.
Review in Parkinson's disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Spinal Cord Stimulation for Gait Disorders in Parkinson's Disease.Journal of Parkinson's disease · 2023Pooled it
- Biomimetic scaffolds based on stem cells for neural tissue engineering: a review.Stem cell research & therapy · 2026Review
- Cellular and Molecular Mechanisms of Neuroprotection in Deep Brain Stimulation for Parkinson's Disease.Biomedicines · 2025Review
- Exploring the role of gut microbiota in Parkinson's disease: insights from fecal microbiota transplantation.Frontiers in neuroscience · 2025Review
- Clinicians' viewpoints on current paradigms of care and research in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Neuromorphic neuromodulation: Towards the next generation of closed-loop neurostimulation.PNAS nexus · 2024Review
- Article
- Changes in deep brain stimulation surgeries between 2019 and 2020: A national inpatient sample analysis.World neurosurgery: X · 2023Article
- Toward a New Generation of Bio-Scaffolds for Neural Tissue Engineering: Challenges and Perspectives.Pharmaceutics · 2023Review
- Predictors of Future Deep Brain Stimulation Surgery in de novo Parkinson's Disease.Movement disorders clinical practice · 2023Article
- Stem Cell Transplantation for Parkinson's Disease: Current Challenges and Perspectives.Aging and disease · 2022Article
- Wireless Power Delivery Techniques for Miniature Implantable Bioelectronics.Advanced healthcare materials · 2021Review
- Evidence-Based Neuroethics, Deep Brain Stimulation and Personality - Deflating, but not Bursting, the Bubble.Neuroethics · 2021Article
- Controlling Alzheimer's Disease Through the Deep Brain Stimulation to Thalamic Relay Cells.Frontiers in computational neuroscience · 2021Article
- Pre-dopa Deep Brain Stimulation: Is Early Deep Brain Stimulation Able to Modify the Natural Course of Parkinson's Disease?Frontiers in neuroscience · 2020Article
- Recent Trends in the Use of Electrical Neuromodulation in Parkinson's Disease.Current behavioral neuroscience reports · 2018Review
- Selection of the Optimal Algorithm for Real-Time Estimation of Beta Band Power during DBS Surgeries in Patients with Parkinson's Disease.Computational intelligence and neuroscience · 2017Article
- Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches.Frontiers in neuroscience · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromodulation of subcortical areas of the brain as therapy to reduce Parkinsonian motor symptoms was developed in the mid-twentieth century and went through many technical and scientific advances that established specific targets and stimulation parameters. Deep Brain Stimulation (DBS) was approved by the FDA in 2002 as neuromodulation therapy for advanced Parkinson's disease, prompting several randomized controlled trials that confirmed its safety and effectiveness. The implantation of tens of thousands of patients in North America and Europe ignited research into its potential role in early disease stages and the therapeutic benefit of DBS compared to best medical therapy. In 2013 the EARLY-STIM trial provided Class I evidence for the use of DBS earlier in Parkinson's disease. This finding led to the most recent FDA approval in patients with at least 4 years of disease duration and 4 months of motor complications as an adjunct therapy for patients not adequately controlled with medications. This following review highlights the historical development and advances made overtime in DBS implantation, the current application, and the challenges that come with it.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.